A Phase 1/2, Multi-Center, Open-Label Clinical Study Evaluating MDX2004 In Participants With Advanced Tumors
Latest Information Update: 06 Oct 2025
At a glance
- Drugs MDX 2004 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors ModeX Therapeutics Inc
Most Recent Events
- 04 Sep 2025 Status changed from not yet recruiting to recruiting.
- 07 Aug 2025 Status changed from planning to not yet recruiting.
- 31 Jul 2025 According to a OPKO Health media release, company has advanced to the fifth dose level in phase 1 clinical trial, with phase 1b studies in selected solid tumors expected in 2026.